Pfizer says its antiviral pill slashes risk of severe COVID-19 by 89%

Pfizer Inc's (PFE.N) experimental antiviral pill to treat COVID-19 was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday, offering what could be a promising new weapon in the fight against the pandemic, SİA reports quoting Reuters.

The trial's results suggest that the oral drug surpasses Merck & Co Inc's (MRK.N) pill, molnupiravir, which was shown last month to halve the risk of dying or being hospitalized for COVID-19 patients at high risk of serious illness.

Bütün xəbərlər Facebook səhifəmizdə